Merck的实验口服药在高危成年人中将LDL胆固醇减少高达60%, Merck’s experimental oral pill reduced LDL cholesterol by up to 60% in high-risk adults, matching injectable drugs without injections.

在对2,912名高危成人进行为期24周的试验中,Merck的实验口服药将LDL胆固醇降低60%,使可注射PCSK9抑制剂有效而无需注射。 Merck’s experimental oral pill enlicitide lowered LDL cholesterol by up to 60% in a 24-week trial of 2,912 high-risk adults, matching injectable PCSK9 inhibitors in effectiveness without requiring injections. 该药物以PCSK9蛋白质为对象,显示出类似于安慰剂的安全情况,52周后持续受益,大多数患者的LDL水平低于55毫克/dL。 The drug, which targets the PCSK9 protein, showed a safety profile similar to placebo and sustained benefits through 52 weeks, with most patients achieving LDL levels below 55 mg/dL. 它尚未得到批准,但Merck计划在2026年初争取林业发展局批准,等待正在进行的大规模试验的结果,以确认心血管病的长期益处。 It is not yet approved, but Merck plans to seek FDA approval in early 2026, pending results from a larger ongoing trial to confirm long-term cardiovascular benefits.